Avoparcin-beta | 73957-87-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Avoparcin-beta
• 英文别名: (1S,18R,19R,22S,25R,28R,40R)-4-[(2S,4R,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-48-[(2S,3R,4S,5S,6R)-3-[(2S,4R,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-49-chloro-22-(3-chloro-4-hydroxyphenyl)-32,35,37-trihydroxy-19-[[(2S)-2-(methylamino)-2-[4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphenyl]acetyl]amino]-20,23,26,42,44-pentaoxo-18-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3(50),4,6(49),8,10,12(48),14(47),15,17(46),29(45),30,32,34(39),35,37-pentadecaene-40-carboxylic acid
• CAS: 73957-87-6
• 化学式: C₈₉H₁₀₁Cl₂N₉O₃₆
• 分子量: 1943.7
• InChiKey: CASDGWYZIKZSQE-ZUWMJMDKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.4
• 重原子数：
  136
• 可旋转键数：
  18
• 环数：
  17.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  710
• 氢给体数：
  26
• 氢受体数：
  39

文献信息

• Processes and host cells for genome, pathway, and biomolecular engineering
  申请人：enEvolv, Inc.

  公开号：US10370654B2

  公开（公告）日：2019-08-06

  The present disclosure provides compositions and methods for genomic engineering.

  本公开提供了基因组工程的组合物和方法。
• Vancomycin analogs
  申请人：——

  公开号：US20020042365A1

  公开（公告）日：2002-04-11

  Compounds that are vancomycin analogs bearing terminal carboxyl group modifications as well as modifications to the vancosamine nitrogen and, optionally, modifications to the C6 position of the glucose residue attached to the amino acid four of the vancomycin heptapeptide chain are disclosed. Methods of making the compounds and methods of using the compounds to treat a bacterial infection in a host are also disclosed.

  本发明公开了万古霉素类似物的化合物，这些化合物具有末端羧基修饰以及万古胺氮的修饰，还可选择修饰连接到万古霉素七肽链氨基酸4的葡萄糖残基的C6位置。还公开了制造这些化合物的方法和使用这些化合物治疗宿主体内细菌感染的方法。
• Desleucyl glycopeptide antibiotics and methods of making same
  申请人：——

  公开号：US20040110665A1

  公开（公告）日：2004-06-10

  Compounds that are analogs of glycopeptide antibiotics are disclosed. The compounds have the formula A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 wherein each of the groups A 2 to A 7 is a modified or unmodified &agr;-amino acid residue, A 1 is optional and, when present, is an organic group other than N-substituted leucine, and at least one of the groups A 1 to A 7 is linked via a glycosidic bond to one or more glycosidic groups each having one or more sugar residues, wherein at least one of said sugar residues is modified to bear at least one hydrophobic substituent. Methods of making these compounds, compositions including these compounds, and methods of using the compounds to treat infections in a host are also disclosed.

  本研究公开了糖肽类抗生素的类似物。这些化合物的化学式为 A 1 -A 2 -A 3 -A 4 -A 5 -A 6 -A 7 其中每个基团 A 2 至 A 7 是修饰或未修饰的&agr;-氨基酸残基，A 1 是可选的，当存在时，是除 N-取代亮氨酸以外的有机基团，且至少有一个基团 A 1 至 A 7 通过糖苷键与一个或多个糖苷基团相连，每个糖苷基团具有一个或多个糖残基，其中至少一个所述糖残基被修饰为具有至少一个疏水取代基。还公开了制造这些化合物的方法、包括这些化合物的组合物以及使用这些化合物治疗宿主感染的方法。
• High potency, mycelial-free avoparcin alkyl sulfate complex, & method for the preparation thereof
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0102499B1

  公开（公告）日：1987-04-22
• TETRAPEPTIDES DERIVING FROM DALBAHEPTIDE ANTIBIOTICS
  申请人：GRUPPO LEPETIT S.p.A.

  公开号：EP0561827B1

  公开（公告）日：1995-04-12